We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chromosome Instability Patterns Predict Tumor Drug Response

By LabMedica International staff writers
Posted on 16 Jun 2022

By analyzing the differences in the number of repetitions of sequences of DNA within cancerous tumors, genomic researchers characterized 17 different types of chromosomal instability, which could be used to predict tumor drug response and to aid in the identifying future drug targets. More...

Chromosomal instability (CIN) is a type of genomic instability in which chromosomes are unstable, such that either whole chromosomes or parts of chromosomes are duplicated or deleted. Chromosomal instability is a common feature of cancer, occurring in around 80% of tumors, researchers are only now beginning to understand exactly what types or patterns of instability are present in any given tumor.

To increase this understanding, investigators at the University of Cambridge (United Kingdom) and colleagues at the Spanish National Cancer Research Center (Madrid, Spain) evaluated the extent, diversity, and origin of CIN across 7,880 tumors representing 33 cancer types.

Results of this evaluation revealed 17 different types of chromosomal instability. These chromosomal instability signatures could be used to predict how tumors might respond to drugs, as well as aiding in the identification of future drug targets.

Senior author Dr. Florian Markowetz, senior group leader at the Cancer Research UK Cambridge Institute of the University of Cambridge, said, "The more complex the genetic changes that underlie a cancer, the more difficult they are to interpret and the more challenging it is to treat the tumor. This is tragically clear from the very low survival rates for cancers that arise as a result of chromosomal instability. Our discovery offers hope that we can turn things around, providing much more sophisticated and accurate treatments. We are now working hard to bring our technology to patients and develop it to a level where it can transform patients' lives."

The CIN study was published in the June 15, 2022, online edition of the journal Nature.

Related Links:
University of Cambridge 
Spanish National Cancer Research Center 

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.